Hereditary Angioedema (HAE) Clinical Trial
Official title:
Demographic and Clinical Characteristics, Treatment Patterns, and Real-world Effectiveness of Lanadelumab in Patients With Hereditary Angioedema Type I or II in the United Kingdom: an Ambispective Cohort Study
The main aim of this study is to compare the HAE attack rate requiring on-demand treatment before and within 2 years after participants with HAE have been treated with lanadelumab. This study is conducted in the United Kingdom where participants were treated or about to be treated with landelumab according to their routine practice at hospitals. Data will be directly collected from participants via study diaries, questionnaires, their medical records, and study doctors treating them. Participants will be contacted every 3 months during study participation (via phone).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02865720 -
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
|
Phase 3 | |
| Completed |
NCT04861090 -
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
|
||
| Recruiting |
NCT05489640 -
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
|
||
| Completed |
NCT02584959 -
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
|
Phase 3 | |
| Completed |
NCT01826916 -
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
|
Phase 2 | |
| Completed |
NCT04057131 -
FIRAZYR General Drug Use-Results Survey (Japan)
|
||
| Recruiting |
NCT05819775 -
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
|
Phase 3 | |
| Recruiting |
NCT05397431 -
A Survey of Lanadelumab in Participants With Hereditary Angioedema
|
||
| Completed |
NCT02741596 -
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
|
Phase 3 | |
| Completed |
NCT02093923 -
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
|
Phase 1 | |
| Completed |
NCT01541423 -
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
|
||
| Completed |
NCT03845400 -
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
|
||
| Completed |
NCT02586805 -
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
|
Phase 3 | |
| Completed |
NCT02052141 -
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
|
Phase 3 | |
| Completed |
NCT03888755 -
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
|
Phase 3 | |
| Recruiting |
NCT05147181 -
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
|
||
| Completed |
NCT05460325 -
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
|
Phase 3 | |
| Completed |
NCT01095510 -
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
|
Phase 2 | |
| Recruiting |
NCT05578417 -
A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
|
||
| Withdrawn |
NCT01253382 -
Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
|
Phase 2/Phase 3 |